Antiangiogenic Therapy for the Treatment of Pediatric Solid Malignancies

Seminars in Pediatric Surgery

Volumn 13, Issue 1, 2004, Pages 53-60

  Davidoff, Andrew M ^a   Kandel, Jessica J ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ADENOVIRUS VECTOR; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CELECOXIB; CILENGITIDE; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DALTEPARIN; ENZASTAURIN; FUMAGILLOL CHLOROACETYLCARBAMATE; HALOFUGINONE; INTERLEUKIN 12; ISOFLAVONE DERIVATIVE; LENALIDOMIDE; MONOCLONAL ANTIBODY LM 609; NAKED DNA; PARVOVIRUS VECTOR; PROTEIN KINASE C INHIBITOR; REBIMASTAT; RETROVIRUS VECTOR; ROFECOXIB; SURAMIN; TEMPOSTATIN; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; ZD 647;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILDHOOD CANCER; CLINICAL TRIAL; DNA MODIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENDOTHELIUM CELL; GENE THERAPY; HEPATOBLASTOMA; HUMAN; LONG TERM CARE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SOLID TUMOR; TRANSGENE;

EID: 1242343612     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2003.09.008     Document Type: Article

References (61)

1. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153, 1995
2. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336, 1991
3. Hamada J, Cavanaugh PG, Lotan O, et al: Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 66:349-354, 1992
4. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188, 1994
5. Brooks PC, Silletti S, von Schalscha TL, et al: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92:391-400, 1998
6. Ruegg C, Yilmaz A, Bieler G, et al: Evidence for the involvement of endothelial cell integrin alpha Vbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4:408-414, 1998
7. Meitar D, Crawford SE, Rademaker AW, et al: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14:405-414, 1996
8. Abramson LP, Grundy PE, Rademaker AW, et al: Increased microvascular density predicts relapse in Wilms' tumor. J Pediatr Surg 38:325-330, 2003
9. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000
10. Zhang L, Yu D, Hu M, et al: Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60:3655-3661, 2000
11. Dameron KM, Volpert OV, Tainsky MA, et al: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994
12. Laughner E, Taghavi P, Chiles K, et al: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1 alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004, 2001
13. Xiong S, Grijalva R, Zhang L, et al: Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 61:1727-1732, 2001
14. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997
15. Essler M, Ruoslahti E: Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci USA 99:2252-2257, 2002
16. Ruoslahti E, Rajotte D: An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 18:813-827, 2000
17. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
18. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
19. Folkman J, Browder T, Palmblad J: Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86:23-33, 2001
20. Kerbel RS, Yu J, Tran J, et al: Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 20:79-86, 2001
21. Celletti FL, Waugh JM, Amabile PG, et al: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7:425-429, 2001
22. Ezekowitz RA, Mulliken JB, Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456-1463, 1992
23. Eggert A, Ikegaki N, Kwiatkowski J, et al: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900-1908, 2000
24. Davidoff AM, Leary MA, Ng CY, et al: Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 36:30-36, 2001
25. Kim ES, Serur A, Huang J, et al: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99:11399-11404, 2002
26. McCrudden KW, Hopkins B, Frischer J, et al: Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis. J Pediatr Surg 38:308-314, 2003
27. Rowe DH, Huang J, Kayton ML, et al: Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 35:30-32, 2000
28. McCrudden KW, Yokoi A, Thosani A, et al: Topotecan is anti-angiogenic in experimental hepatoblastoma. J Pediatr Surg 37:857-861, 2002
29. Soffer SZ, Moore JT, Kim E, et al: Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 36:1177-1181, 2001
30. Soffer SZ, Kim E, Moore JT, et al: Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J Pediatr Surg 36:1781-1784, 2001
31. Abramson LP, Stellmach V, Doll JA, et al: Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J Pediatr Surg 38:336-342, 2003
32. Matsusaka S, Nakasho K, Terada N, et al: Inhibition by an angiogenesis inhibitor, TNP-470, of the growth of a human hepatoblastoma heterotransplanted into nude mice. J Pediatr Surg 35:1198-1204, 2000
33. Nagabuchi E, VanderKolk WE, Une Y, et al: TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 32:287-293, 1997
34. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
35. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
36. Rowe DH, Huang J, Li J, et al: Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35:977-981, 2000
37. Huang J, Moore J, Soffer S, et al: Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 36:357-361, 2001
38. Zhu Z, Hattori K, Zhang H, et al: Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17:604-611, 2003
39. Gerber HP, Kowalski J, Sherman D, et al: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253-6258, 2000
40. Feldman AL, Libutti SK: Progress in antiangiogenic gene therapy of cancer. Cancer 89:1181-1194, 2000
41. Davidoff AM, Leary MA, Ng CY, et al: Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 36:30-36, 2001
42. Davidoff AM, Leary MA, Ng CY, et al: Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo. Med Pediatr Oncol 35:638-640, 2000
43. Asahara T, Masuda H, Takahashi T, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228, 1999
44. Davidoff AM, Ng CY, Brown P, et al: Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 7:2870-2879, 2001
45. Davidoff AM, Nathwani AC, Spurbeck WW, et al: rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res 62:3077-3083, 2002
46. Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998, 1999
47. Tolsma SS, Volpert OV, Good DJ, et al: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511, 1993
48. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
49. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285 1997
50. Pike SE, Yao L, Jones KD, et al: Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188:2349-2356, 1998
51. Zhai Y, Ni J, Jiang GW, et al: VEG1, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that sup presses the growth of colon carcinomas in vivo. FASEB J 13:181-189, 1999
52. Gupta SK, Hassel T, Singh JP: A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 92:7799-7803, 1995
53. Clapp C, Martial JA, Guzman RC, et al: The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133:1292-1299, 1993
54. Ramchandran R, Dhanabal M, Volk R, et al: Antiangiogenic activity of restin, NC10 domain of human collagen XV: Comparison to endostatin, Biochem Biophys Res Commun 255:735-739, 1999
55. Jackson D, Volpert OV, Bouck N, et al: Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 266:1581-1584, 1994
56. Hasselaar P, Sage EH: SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 49:272-283, 1992
57. Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47:5155-5161, 1987
58. Sage EH: Pieces of eight: Bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends Biol Sci 7:182, 1999
59. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997
60. O'Reilly MS, Pirie-Shepherd S, Lane WS, et al: Antiangiogenic activity of the cleaved conformation of the Serpin Antithrombin III. Science 285:1926-1928, 1999
61. Strieter RM, Kunkel SL, Arenberg DA, et al: Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun. 210:51-57, 1997